Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O43526
UPID:
KCNQ2_HUMAN
Alternative names:
KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2
Alternative UPACC:
O43526; O43796; O75580; O95845; Q4VXP4; Q4VXR6; Q5VYT8; Q96J59; Q99454
Background:
Potassium voltage-gated channel subfamily KQT member 2 (Kv7.2), also known as KQT-like 2 or Neuroblastoma-specific potassium channel subunit alpha KvLQT2, plays a pivotal role in neuronal excitability. It forms a potassium channel with KCNQ3, crucial for the M-current that regulates neurons' response to stimuli. This channel's activity is influenced by various compounds, including linopirdine and retigabine.
Therapeutic significance:
Kv7.2 is implicated in severe neurological disorders, such as benign familial neonatal seizures 1 and developmental and epileptic encephalopathy 7, characterized by early-life seizures and potential developmental delays. Understanding Kv7.2's role could lead to novel treatments for these conditions.